HOME >> MEDICINE >> NEWS
First large-scale clinical study establishes the efficacy of the new oral anticoagulant H 376/95

at high risk of venous thrombosis (formation of a blood clot in a vein) which may result in pulmonary embolism leading to death. A common approach to prevention of venous thromboembolism is the use of anticoagulant prophylaxis e.g. injectable low molecular weight heparin or oral warfarin. Warfarin requires careful and regular coagulation monitoring i.e. taking blood samples. Warfarin has limitations because of a slow onset of effect over several days. Also, bleeding complications and drug interactions are common. There is, therefore, a need for an effective and well-tolerated oral alternative to warfarin. The data from the METHRO II study indicate that H 376/95 shows considerable promise as a replacement for low molecular weight heparin and warfarin in the prophylaxis of venous thromboembolism in orthopaedic surgery."

The METHRO II study was a double-blind, dose-finding study and a comparator agent was used. The primary purpose of the study was to determine the dose-response relationship with regard to efficacy for the oral direct thrombin inhibitor, H 376/95, preceded by subcutaneous administration of melagatran. The METHRO II study was also designed to compare the efficacy of the H 376/95 regimen with conventional prophylaxis using the injectable low molecular weight heparin agent, dalteparin.

Patients were randomised to one of four melagatran/H 376/95 regimens or dalteparin for 8-11 days. The regimens were: 1mg, 1.5mg, 2.25mg or 3mg melagatran subcutaneously twice daily followed by 8mg, 12mg, 18mg or 24mg oral H 376/95 twice daily respectively or dalteparin 5000 IU once daily subcutaneously. A diagnostic procedure, phlebography, was carried out on the final day of treatment. Patient follow-up was 4-6 weeks post-operatively. Two-thirds of the patients underwent hip replacement and one-third knee replacement surgery. The age range was 18-85 years.

There was a clear relationship between the dose regimen of H 376/95 and the occurrence of
'"/>

Contact: Jonathan Wilson/Rebecca Hunt
jonathan.wilson@ketchumcomms.co.uk
44-207-465-7698
Ketchum
4-May-2000


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released a ... are available at low rates up to 30% off. ... new emergency doors. The emergency door adopts fireproof material ... several colors. All of the products are top-quality guaranteed. ... not as easy as many people think. As ...
(Date:11/23/2014)... To show thanks to new and old customers, iFitDress.com ... dresses for weddings. Customers who need custom outfits can ... distinguished dress manufacturer, and it is among the ones which ... very long time. The CEO of this company says, "iFitDress.com ... to buy not only a beautiful dress, but also a ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... Asher Milgrom, is a celebrity ... was recently featured on International Business Times. ... CEO of American Medical Aesthetics & Wellness, also known ... full scholarship to attend an M.D./Ph.D program at University ... University of Chicago, where his field of study was ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 The FDA ... in Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? ... , The FDA’s focus on promotional activities is no ... , Now they're looking at websites, Twitter, journal articles, ... calendar for Thursday, Dec. 11, for On-Demand access to ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5
(Date:11/21/2014)... VIENNA, Va. , Nov. 21, 2014  Alta ... in Southern California , today announced ... technology. Alta will be providing the innovative BeClose system ... Logo - http://photos.prnewswire.com/prnh/20141121/160143LOGO ... providing the kind of affordable 24/7 care our clients ...
(Date:11/21/2014)... SAN CLEMENTE, Calif. , Nov. 21, 2014 /PRNewswire/ ... Lab Coats and Performance Scrubs carried out a new ... the medical industry,s very first "limited edition" lab ... the first female professors of surgery in the world. ... departure from its unisex predecessors, with a sleek envelope ...
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
Cached News: